We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

167 hedge funds and large institutions have $2.37B invested in Agios Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 84 increasing their positions, 34 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 34

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

7% more funds holding

Funds holding: 156 → 167 (+11)

1% less capital invested

Capital invested by funds: $2.39B → $2.37B (-$19.4M)

1.34% less ownership

Funds ownership: 97.02% → 95.68% (-1.3%)

38% less call options, than puts

Call options by funds: $11.1M | Put options by funds: $17.9M

43% less funds holding in top 10

Funds holding in top 10: 7 → 4 (-3)

Holders
167
Holders Change
+11
Holders Change %
+7.05%
% of All Funds
4.16%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.1%
New
28
Increased
84
Reduced
34
Closed
16
Calls
$11.1M
Puts
$17.9M
Net Calls
-$6.77M
Net Calls Change
-$3.2M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$45.8M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$43.7M
3
Invesco
Invesco
Georgia
+$34.3M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$31.6M
5
BlackRock
BlackRock
New York
+$26M

Top Sellers

1
FP
Flagship Pioneering
Massachusetts
-$56.4M
2
RG
Redmile Group
California
-$11.3M
3
CGT
Capital Guardian Trust
California
-$7.88M
4
GTC
Ghost Tree Capital
New York
-$7.3M
5
Capital Fund Management (CFM)
Capital Fund Management (CFM)
France
-$5.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
MFW
151
Mosaic Family Wealth
Missouri
$10K +$10.2K +200 New
TRCT
152
Tower Research Capital (TRC)
New York
$9K +$9.2K +180 New
QT
153
Quantbot Technologies
New York
$8K -$6.85K -134 -46%
VNA
154
Valley National Advisers
Pennsylvania
$8K – – –
WTC
155
WhitTier Trust Company
Nevada
$7K +$7.16K +140 New
US Bancorp
156
US Bancorp
Minnesota
$6K -$3.58K -70 -38%
Bessemer Group
157
Bessemer Group
New Jersey
$6K – – –
Envestnet Asset Management
158
Envestnet Asset Management
Illinois
$6K +$1.18K +23 +24%
KF
159
Krilogy Financial
Missouri
$5K +$5.11K +100 New
SBL
160
Sargent Bickham Lagudis
Colorado
$4K – – –
MAM
161
Meeder Asset Management
Ohio
$3K -$1.43K -28 -31%
TG
162
TLP Group
Illinois
$3K +$2.96K +58 New
PNC Financial Services Group
163
PNC Financial Services Group
Pennsylvania
$2K -$7.21K -141 -76%
ASN
164
Advisory Services Network
Georgia
$2K – – –
TFO
165
Tarbox Family Office
California
$1K – – –
SEI Investments
166
SEI Investments
Pennsylvania
$1K +$409 +8 +53%
Walleye Trading
167
Walleye Trading
New York
$5 +$5.11K +100 New
FP
168
Flagship Pioneering
Massachusetts
– -$56.4M -965,369 Closed
GTC
169
Ghost Tree Capital
New York
– -$7.3M -125,000 Closed
Capital Fund Management (CFM)
170
Capital Fund Management (CFM)
France
– -$5.15M -88,185 Closed
Millennium Management
171
Millennium Management
New York
– -$2.19M -37,506 Closed
PP
172
Paloma Partners
Connecticut
– -$1.23M -20,977 Closed
OAM
173
Oxford Asset Management
United Kingdom
– -$807K -13,814 Closed
AQR Capital Management
174
AQR Capital Management
Connecticut
– -$687K -11,764 Closed
CCM
175
Cadence Capital Management
Massachusetts
– -$621K -10,635 Closed
4 5 6
7
8

AGIO Hedge Fund Activity: Q2 2017 in Review

167 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2017, worth a combined $2.37B — down 0.81% from $2.39B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new AGIO positions and 16 closed out — a net gain of 12 holders — while 84 added to existing stakes and 34 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $45.8M. The largest seller was Flagship Pioneering, exiting entirely with an estimated $56.4M sold.

  • 167 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2017, up from 156 in Q1 2017.
  • Funds reported $2.37B of Agios Pharmaceuticals stock for Q2 2017, down 0.81% quarter-over-quarter.
  • 28 funds opened new Agios Pharmaceuticals positions in Q2 2017 and 16 closed out, a net change of +12 holders.
  • The largest Agios Pharmaceuticals buyer in Q2 2017 was Fidelity Investments, an estimated $45.8M added.
  • The largest Agios Pharmaceuticals seller in Q2 2017 was Flagship Pioneering, an estimated $56.4M sold.

Based on aggregated 13F filings for Q2 2017.